Vaxcyte stock holds near USD 60.37 as estimates shift

Published on 09/18/2026 at 14:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaxcyte stock closed at USD 60.37 on September 17, 2026, up 2.72 percent. Yahoo Finance shows Q2 2026 EPS of -1.97 and 2027 revenue estimates at USD 87.15 million.

PCVX, US92242T1016, Illustration mit AI erstellt.

Vaxcyte stock (US92242T1016) closed at USD 60.37 on September 17, 2026, up 2.72 percent on the day. Yahoo Finance shows Q2 2026 EPS of -1.97 versus an estimate of -2.10, while 2027 revenue estimates stand at USD 87.15 million.

Estimates stay anchored

Yahoo Finance lists 9 analysts for the current quarter and 9 for next year, with revenue estimates for the September 2026 quarter still blank and the 2027 average at USD 87.15 million. The same table shows current-year EPS estimates of -8.2, unchanged from 7 days ago, and next-year EPS at -7.22.

That leaves the comparison clear: the June 30, 2026 quarter delivered EPS of -1.97, which was 0.13 better than the -2.10 estimate and marked a 6.06 percent surprise. The stock now trades against a forecast path that still assumes a loss, not a return to earnings.

Company figures

Reuters describes Vaxcyte as a clinical-stage vaccine company with a pipeline centered on VAX-31, VAX-24 and VAX-XL. Reuters also says VAX-31 is being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, a detail that matters more to valuation than the day-to-day quote.

The latest Reuters company profile also lists 2025 net income at USD -766.628 million, total assets at USD 3,002.717 million and total liabilities at USD 317.207 million. For investors, the balance sheet still reflects a development-stage company that is spending heavily before any commercial revenue scale arrives.

Stock level

Vaxcyte stock finished September 17, 2026 at USD 60.37 on NasdaqGS, with the same session change at +2.72 percent. The move sits alongside a 52-week range and market-cap snapshot that should be read against the September 2026 estimate set and the June 30, 2026 EPS print.